Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $9.00 Consensus Price Target from Brokerages

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have been assigned an average recommendation of “Hold” from the six brokerages that are currently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold rating. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $9.00.

A number of research firms have recently commented on ACRS. HC Wainwright restated a “neutral” rating on shares of Aclaris Therapeutics in a report on Tuesday, September 17th. StockNews.com upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 25th.

Aclaris Therapeutics Stock Performance

Shares of ACRS opened at $2.09 on Wednesday. Aclaris Therapeutics has a 1 year low of $0.59 and a 1 year high of $5.71. The company’s 50 day simple moving average is $1.25 and its 200 day simple moving average is $1.22. The company has a market capitalization of $149.11 million, a price-to-earnings ratio of -2.55 and a beta of 0.20.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.04. The firm had revenue of $2.77 million for the quarter, compared to analyst estimates of $1.74 million. Aclaris Therapeutics had a negative return on equity of 53.18% and a negative net margin of 183.28%. Equities analysts expect that Aclaris Therapeutics will post -0.65 EPS for the current fiscal year.

Institutional Trading of Aclaris Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. purchased a new position in Aclaris Therapeutics in the first quarter valued at about $39,000. SG Americas Securities LLC grew its stake in shares of Aclaris Therapeutics by 69.5% in the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 13,461 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of Aclaris Therapeutics by 5,265.1% in the first quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 61,602 shares in the last quarter. Deuterium Capital Management LLC acquired a new position in Aclaris Therapeutics during the 1st quarter worth approximately $99,000. Finally, Marquette Asset Management LLC acquired a new stake in Aclaris Therapeutics in the first quarter valued at approximately $104,000. 98.34% of the stock is owned by hedge funds and other institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.